RxDoctor Payments Data

Beth Frederick

Psychiatric/Mental Health · Terre Haute, INNPI 1699371500

Payments from drug & device makers

$2,623in general payments, 2019–2025

Across 119 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$909
  • Alkermes, Inc.$383
  • Otsuka America Pharmaceutical, Inc.$354
  • E.r. Squibb & Sons, L.L.C.$247
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
  • Axsome Therapeutics, Inc.$125
  • plus $377 from 6 others

What the payments were for

  • Food & beverage$2,56798%
  • Education$562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,623 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$9,572
Medicare patients
26
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$162,029
AustedoDeutetrabenazine18$86,091
Austedo XrDeutetrabenazine14$83,713
AristadaAripiprazole Lauroxil19$63,065
CaplytaLumateperone Tosylate35$56,582
AtivanLorazepam12$51,663
VraylarCariprazine Hcl25$35,647
UzedyRisperidone13$35,106
Zyprexa RelprevvOlanzapine Pamoate36$31,315
FanaptIloperidone15$30,336
Paliperidone ErPaliperidone64$23,400
Clozapine113$15,226
BelsomraSuvorexant29$12,704
AuvelityDextromethorphan Hbr/Bupropion11$11,742
Aripiprazole65$11,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy$84$204,91145 claims
Johnson & JohnsonInvega Sustenna$909$162,02947 claims
Alkermes, Inc.Aristada$383$63,06519 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$228$56,58235 claims
AbbVieVraylar$95$35,64725 claims
Axsome Therapeutics, Inc.Auvelity$125$11,74211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →